Each year, the Global Business Coalition honours global pioneers in the fight against HIV/AIDS, tuberculosis and malaria. Sanofi-aventis won the Core Competence award for this partnership with DNDi to develop and distribute the anti-malarial treatment, Artesunate Amodiaquine Winthrop®/Coarsucam™ (“ASAQ”), indicated in the treatment of uncomplicated malaria due to Plasmodium falciparum. The ASAQ program is the first example of an antimalarial treatment to be produced through a public private partnership.

Taken once daily, for three days, the drug has been specifically designed to target children and adults living in some of the most difficult conditions in sub-saharan Africa by providing the simplest possible dosing regimen, colour codes and pictograms on blisters to minimise the risk of confusion between dosages, especially for illiterate patients. Provided at low cost – less than 1 US $ for an adult treatment and less than 0.50 US $ for children – to non-profit institutions, ASAQ is designed to improve patient compliance and reduce the risk of malaria parasites developing resistance to the disease. ASAQ was pre-qualified by the World Health Organization (WHO) in 2008 and, since then, more than 50 million ASAQ treatments have been distributed in sub-saharan African countries.
 

• Read the press release dated May 25, 2010
   

• Coarsucam™ SmPC   (PDF, 116Kb)
• Artesunate Amodiaquine Winthrop® SmPC   (PDF, 116Kb)